# A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)

> **NCT05190471** · PHASE1 · RECRUITING · sponsor: **Bio-Path Holdings, Inc.** · enrollment: 48 (estimated)

## Conditions studied

- Acute Myeloid Leukemia, in Relapse
- Acute Myeloid Leukemia Refractory

## Interventions

- **DRUG:** BP1002; Liposomal Bcl-2 Antisense Oligodeoxynucleotide
- **DRUG:** Decitabine (in combination with BP1002)

## Key facts

- **NCT ID:** NCT05190471
- **Lead sponsor:** Bio-Path Holdings, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-08-16
- **Primary completion:** 2027-03
- **Final completion:** 2027-09
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2025-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05190471

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05190471, "A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05190471. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*